Japanese researchers have achieved a groundbreaking feat by removing the extra chromosome that causes Down syndrome, using CRISPR gene-editing technology to restore normal cell function.

The study, led by Dr. Ryotaro Hashizume at Mie University, marks the first time scientists have targeted the root cause of Down syndrome at the cellular level. Their method eliminates the third copy of chromosome 21 while preserving the normal two—a milestone that could transform genetic medicine.

Down syndrome, affecting about one in 700 births worldwide, is the result of trisomy 21, where an extra chromosome disrupts normal development. The condition is associated with intellectual disabilities, distinct facial characteristics, and a higher risk of health problems such as heart disease and early-onset Alzheimer’s.

To correct this, the Japanese team employed a technique known as allele-specific editing. By directing CRISPR-Cas9 to DNA sequences unique to the extra chromosome, they were able to cut and destabilize it, leading to its natural loss as cells divided.

Laboratory tests showed promising results: the additional chromosome was removed in 30.6% of treated cells. These cells displayed normalized gene expression, protein production, and survival rates—closely resembling healthy cells. Importantly, the approach proved effective in both stem cells and adult skin cells taken from individuals with Down syndrome.

While clinical applications remain years away, the research offers a glimpse into a future where therapies could ease or even prevent some of the most severe health complications linked to the condition. For families and individuals affected by Down syndrome, it represents one of the most hopeful scientific advances to date.